MacroGenics Inc. announced a partnership with Eversana to commercialize margetuximab in the United States, if approved.

Urovant Sciences and Genmab reported disappointing clinical trial announcements.

The U.S. government will start distributing Regeneron Pharmaceuticals Inc.’s newly authorized Covid-19 antibody combination on Nov. 24, beginning with more than 30,000 treatment courses, a health official said.

The U.S. Food and Drug Administration issued emergency use authorization for Regeneron Pharmaceuticals Inc.’s Covid-19 antibody therapy, an experimental treatment given to U.S. President Donald Trump that he said helped cure him of the disease.

AstraZeneca started late-stage trials of an experimental long-acting monoclonal antibody combination drug the company hopes could be used as a so-called prophylactic to prevent Covid-19 infection in at-risk people for up to 12 months.

The U.S. Food and Drug Administration issued a Complete Response Letter (CRL) for Sanofi’s blood cancer treatment sutimlimab.

There are some questions about how effective Eli Lilly’s antibody neutralizing antibody bamlanivimab (LY-CoV555) will prove to be in the battle against Covid-19 due to labeling limitations.

U.S. regulators authorized emergency use of the first experimental antibody drug for Covid-19 in patients who are not hospitalized but are at risk of serious illness because of their age or other conditions.

A World Health Organization-led scheme to supply Covid-19 drugs to poor countries is betting on experimental monoclonal antibody treatments and steroids but shunning Gilead’s remdesivir therapy, an internal document shows.

Additional findings from Biogen’s Phase II LILAC study show the biotech company’s lupus drug candidate BIIB059 is superior to placebo for reducing joint disease activity in patients with systemic lupus erythematosus (SLE).